• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PainReform Ltd. (Amendment)

    3/2/23 4:30:40 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRFX alert in real time by email
    SC 13G/A 1 zk2329293.htm SC 13G/A

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     


     
    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)*
     
    PainReform Ltd.
     
    (Name of Issuer)
     
    Ordinary Shares, par value NIS 0.03 per share
     
    (Title of Class of Securities)
     
    M77798102
     
    (CUSIP Number)
     
    December 31, 2022
     
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     


    ☐ Rule 13d-1(b)

     


    ☐ Rule 13d-1(c)

     


    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     


    CUSIP No. M77798102 13G Page 2 of 19 Pages

     

    1.

    Names of Reporting Persons.

     

    Medica III Management Co.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with

    5.

    Sole Voting Power

     

    3,292,250 (1)
    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    3,292,250 (1)
    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,292,250 (1)
    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    31.0% (1)
    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)
    This amount of shares and percentage relates to all the Reporting Persons and is based on 10,634,166 Ordinary Shares of the Issuer’s issued and outstanding as of September 30, 2022, which number appeared in the Issuer’s unaudited condensed financial statements as of September 30, 2022, filed as Exhibit 99.1 to its Current Report on Form 6-K, filed with the Securities and Exchange Commission (“SEC”) on November 14, 2022.

     



     

    CUSIP No. M77798102 13G Page 3 of 19 Pages

     

    1.

    Names of Reporting Persons.

     

    Medica III Management L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with

    5.

    Sole Voting Power

     

    3,292,250 (1)
    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    3,292,250 (1)
    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,292,250 (1)
    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    31.0% (1)
    12.

    Type of Reporting Person (See Instructions)

     

    CO

     

    (1)
    This amount of shares and percentage relates to all the Reporting Persons and is based on 10,634,166 Ordinary Shares of the Issuer’s issued and outstanding as of September 30, 2022, which number appeared in the Issuer’s unaudited condensed financial statements as of September 30, 2022, filed as Exhibit 99.1 to its Current Report on Form 6-K, filed with the SEC on November 14, 2022.

     



     

    CUSIP No. M77798102 13G Page 4 of 19 Pages

     

    1.

    Names of Reporting Persons.

     

    Medica III Investments (International) L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with

    5.

    Sole Voting Power

     

    3,292,250 (1)
    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    3,292,250 (1)
    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,292,250 (1)
    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    31.0% (1)
    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)
    This amount of shares and percentage relates to all the Reporting Persons and is based on 10,634,166 Ordinary Shares of the Issuer’s issued and outstanding as of September 30, 2022, which number appeared in the Issuer’s unaudited condensed financial statements as of September 30, 2022, filed as Exhibit 99.1 to its Current Report on Form 6-K, filed with the SEC on November 14, 2022.

     



     

    CUSIP No. M77798102 13G Page 5 of 19 Pages

     

    1.

    Names of Reporting Persons.

     

    Medica III Investments (Israel) L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Israel

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with

    5.

    Sole Voting Power

     

    3,292,250 (1)
    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    3,292,250 (1)
    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,292,250 (1)
    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    31.0% (1)
    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)
    This amount of shares and percentage relates to all the Reporting Persons and is based on 10,634,166 Ordinary Shares of the Issuer’s issued and outstanding as of September 30, 2022, which number appeared in the Issuer’s unaudited condensed financial statements as of September 30, 2022, filed as Exhibit 99.1 to its Current Report on Form 6-K, filed with the SEC on November 14, 2022.

     



     

    CUSIP No. M77798102 13G Page 6 of 19 Pages

     

    1.

    Names of Reporting Persons.

     

    Medica III Investments (S.F.) L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with

    5.

    Sole Voting Power

     

    3,292,250 (1)
    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    3,292,250 (1)
    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,292,250 (1)
    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    31.0% (1)
    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)
    This amount of shares and percentage relates to all the Reporting Persons and is based on 10,634,166 Ordinary Shares of the Issuer’s issued and outstanding as of September 30, 2022, which number appeared in the Issuer’s unaudited condensed financial statements as of September 30, 2022, filed as Exhibit 99.1 to its Current Report on Form 6-K, filed with the SEC on November 14, 2022.

     



     

    CUSIP No. M77798102 13G Page 7 of 19 Pages

     

    1.

    Names of Reporting Persons.

     

    Medica III Investments (P.F.) L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Israel

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with

    5.

    Sole Voting Power

     

    3,292,250 (1)
    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    3,292,250 (1)
    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,292,250 (1)
    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    31.0% (1)
    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)
    This amount of shares and percentage relates to all the Reporting Persons and is based on 10,634,166 Ordinary Shares of the Issuer’s issued and outstanding as of September 30, 2022, which number appeared in the Issuer’s unaudited condensed financial statements as of September 30, 2022, filed as Exhibit 99.1 to its Current Report on Form 6-K, filed with the SEC on November 14, 2022.

     



     

    CUSIP No. M77798102 13G Page 8 of 19 Pages

     

    1.

    Names of Reporting Persons.

     

    Medica III Investments (Israel) (B) L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Israel

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with

    5.

    Sole Voting Power

     

    3,292,250 (1)
    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    3,292,250 (1)
    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,292,250 (1)
    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    31.0% (1)
    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)
    This amount of shares and percentage relates to all the Reporting Persons and is based on 10,634,166 Ordinary Shares of the Issuer’s issued and outstanding as of September 30, 2022, which number appeared in the Issuer’s unaudited condensed financial statements as of September 30, 2022, filed as Exhibit 99.1 to its Current Report on Form 6-K, filed with the SEC on November 14, 2022.

     



     

    CUSIP No. M77798102 13G Page 9 of 19 Pages

     

    1.

    Names of Reporting Persons.

     

    Poalim Medica III Investments L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Israel

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with

    5.

    Sole Voting Power

     

    3,292,250 (1)
    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    3,292,250 (1)
    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,292,250 (1)
    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    31.0% (1)
    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)
    This amount of shares and percentage relates to all the Reporting Persons and is based on 10,634,166 Ordinary Shares of the Issuer’s issued and outstanding as of September 30, 2022, which number appeared in the Issuer’s unaudited condensed financial statements as of September 30, 2022, filed as Exhibit 99.1 to its Current Report on Form 6-K, filed with the SEC on November 14, 2022.

     



     

    CUSIP No. M77798102 13G Page 10 of 19 Pages

     

    1.

    Names of Reporting Persons.

     

    Ehud Geller

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Israel

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,292,250 (1)
    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,292,250 (1)
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,292,250 (1)
    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    31.0% (1)
    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)
    This amount of shares and percentage relates to all the Reporting Persons and is based on 10,634,166 Ordinary Shares of the Issuer’s issued and outstanding as of September 30, 2022, which number appeared in the Issuer’s unaudited condensed financial statements as of September 30, 2022, filed as Exhibit 99.1 to its Current Report on Form 6-K, filed with the SEC on November 14, 2022.

     



     

    CUSIP No. M77798102 13G Page 11 of 19 Pages

     

    1.

    Names of Reporting Persons.

     

    Batsheva Elran

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Israel

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,292,250 (1)
    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,292,250 (1)
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,292,250 (1)
    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.

    Percent of Class Represented by Amount in Row (9)

     

    31.0% (1)
    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)
    This amount of shares and percentage relates to all the Reporting Persons and is based on 10,634,166 Ordinary Shares of the Issuer’s issued and outstanding as of September 30, 2022, which number appeared in the Issuer’s unaudited condensed financial statements as of September 30, 2022, filed as Exhibit 99.1 to its Current Report on Form 6-K, filed with the SEC on November 14, 2022.

     



     

    Item 1(a). Name of Issuer:

     

    The name of the issuer is PainReform Ltd.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    The Issuer’s principal executive offices are located at 60C Medinat Hayehudim, Herzliya, 4676652, Israel.

     

    Item 2(a). Name of Person Filing:

     

    The following entity and individuals, listed in (i)-(viii) below, who are filing this Statement of Beneficial Ownership on Schedule 13G (this “Statement”), are referred to herein collectively as the “Reporting Persons”:

     

    General Partners:

     

    Medica III Management Co., a Cayman Islands corporation

     

    Medica III Management L.P., a Cayman Islands limited partnership

     

    Investment Funds:

     

    Medica III Investments (International) L.P. a Cayman Islands limited Partnership

     

    Medica III Investments (Israel) L.P. an Israeli limited partnership

     

    Medica III Investments (S.F.) L.P. a Cayman Islands limited partnership

     

    Medica III Investments (P.F.) L.P. an Israeli limited partnership

     

    Medica III Investments (Israel) (B) L.P. an Israeli limited partnership

     

    Poalim Medica III Investments L.P. an Israeli limited partnership

     


    Officers/Directors:


    Ehud Geller, an Israeli citizen and an officer and director of Medica III Investment group.

     

    Batsheva Elran, an Israeli citizen and an officer and director of Medica III Investment group.

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    The principal business office of each Reporting Person is as follows:

     

    c/o Medica III Investment Group

    60C Medinat Hayehudim

    Herzliya, 44676652, Israel

     

    Item 2(c). Citizenship:

     

    Each of the entities or persons identified in Item 2(a) above is a corporation, limited partnership or individual organized under the laws of the jurisdiction, or is a citizen of the jurisdiction, as applicable, set forth opposite such entity’s or person’s name.

     



     

    Item 2(d). Title of Class of Securities:

     

    Ordinary shares, par value NIS 0.03 per share.

     

    Item 2(e). CUSIP Number:

     

    The CUSIP number of the Ordinary Shares is M77798102.

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ☐

    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

           
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Not applicable.

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     


    I. Medica III Management Co. is the general partner of Medica III Management L.P., the general partner of each of the investments funds named in Item 2(a) above:

     


    (a)
    Amount beneficially owned together with all other Reporting Persons: 3,292,250 Ordinary Shares

     


    (b)
    Percent of class*: 31.0%

     



     


    (c)
    Number of shares as to which the person together with all other Reporting Persons has:

     


    (i)
    Sole power to vote or to direct the vote: 3,292,250

     


    (ii) Shared power to vote or to direct the vote: 0

     


    (iii)
    Sole power to dispose of or to direct the disposition of: 3,292,250

     


    (iv) Shared power to dispose of or to direct the disposition of: 0

     


    II. Medica III Management Co. is the general partner of each of the investment funds named in Item 2(a) above:

     


    (a)
    Amount beneficially owned together with all other Reporting Persons: 3,292,250 Ordinary Shares

     


    (b)
    Percent of class*: 31.0%

     


    (c)
    Number of shares as to which the person together with all other Reporting Persons has:

     


    (i)
    Sole power to vote or to direct the vote: 3,292,250

     


    (ii) Shared power to vote or to direct the vote: 0

     


    (iii)
    Sole power to dispose of or to direct the disposition of: 3,292,250

     


    (iv) Shared power to dispose of or to direct the disposition of: 0

     


    III. Medica III Investments (International) L.P.

     


    (a)
    Amount beneficially owned together with all other Reporting Persons: 3,292,250 Ordinary Shares

     


    (b)
    Percent of class*: 31.0%

     


    (c) Number of shares as to which the person together with all other Reporting Persons has:

     


    (i)
    Sole power to vote or to direct the vote: 3,292,250

     


    (ii) Shared power to vote or to direct the vote: 0

     


    (iii)
    Sole power to dispose of or to direct the disposition of: 3,292,250

     


    (iv) Shared power to dispose of or to direct the disposition of: 0

     


    IV. Medica III Investments (Israel) L.P.

     


    (a)
    Amount beneficially owned together with all other Reporting Persons: 3,292,250 Ordinary Shares

     


    (b)
    Percent of class*: 31.0%

     


    (c) Number of shares as to which the person together with all other Reporting Persons has:

     


    (i)
    Sole power to vote or to direct the vote: 3,292,250

     


    (ii) Shared power to vote or to direct the vote: 0

     


    (iii)
    Sole power to dispose of or to direct the disposition of: 3,292,250

     


    (iv) Shared power to dispose of or to direct the disposition of: 0

     



     


    V. Medica III Investments (S.F.) L.P.

     


    (a)
    Amount beneficially owned together with all other Reporting Persons: 3,292,250 Ordinary Shares

     


    (b)
    Percent of class*: 31.0%

     


    (c) Number of shares as to which the person together with all other Reporting Persons has:

     


    (i)
    Sole power to vote or to direct the vote: 3,292,250

     


    (ii) Shared power to vote or to direct the vote: 0

     


    (iii)
    Sole power to dispose of or to direct the disposition of: 3,292,250

     


    (iv) Shared power to dispose of or to direct the disposition of: 0

     


    VI. Medica III Investments (P.F.) L.P.

     


    (a)
    Amount beneficially owned together with all other Reporting Persons: 3,292,250 Ordinary Shares

     


    (b)
    Percent of class*: 31.0%

     


    (c) Number of shares as to which the person together with all other Reporting Persons has:

     


    (i)
    Sole power to vote or to direct the vote: 3,292,250

     


    (ii) Shared power to vote or to direct the vote: 0

     


    (iii)
    Sole power to dispose of or to direct the disposition of: 3,292,250

     


    (iv) Shared power to dispose of or to direct the disposition of: 0

     


    VII. Medica III Investments (Israel) (B) L.P.

     


    (a)
    Amount beneficially owned together with all other Reporting Persons: 3,292,250 Ordinary Shares

     


    (b)
    Percent of class*: 31.0%

     


    (c) Number of shares as to which the person together with all other Reporting Persons has:

     


    (i)
    Sole power to vote or to direct the vote: 3,292,250

     


    (ii) Shared power to vote or to direct the vote: 0

     


    (iii)
    Sole power to dispose of or to direct the disposition of: 3,292,250

     


    (iv) Shared power to dispose of or to direct the disposition of: 0

     


    VIII. Poalim Medica III Investments L.P.

     


    (a)
    Amount beneficially owned together with all other Reporting Persons: 3,292,250 Ordinary Shares

     


    (b)
    Percent of class*: 31.0%

     


    (c) Number of shares as to which the person together with all other Reporting Persons has:

     


    (i)
    Sole power to vote or to direct the vote: 3,292,250

     


    (ii) Shared power to vote or to direct the vote: 0

     


    (iii)
    Sole power to dispose of or to direct the disposition of: 3,292,250

     


    (iv) Shared power to dispose of or to direct the disposition of: 0


     


    IX. Ehud Geller

     


    (a)
    Amount beneficially owned together with all other Reporting Persons: 3,292,250 Ordinary Shares

     


    (b)
    Percent of class*: 31.0%

     


    (c) Number of shares as to which the person together with all other Reporting Persons has:

     


    (i) Sole power to vote or to direct the vote: 0

     


    (ii)
    Shared power to vote or to direct the vote: 3,292,250

     


    (iii) Sole power to dispose of or to direct the disposition of: 0

     


    (iv)
    Shared power to dispose of or to direct the disposition of: 3,292,250

     


    X. Batsheva Elran

     


    (a)
    Amount beneficially owned together with all other Reporting Persons: 3,292,250 Ordinary Shares

     


    (b)
    Percent of class*: 31.0%

     


    (c) Number of shares as to which the person together with all other Reporting Persons has:

     


    (i) Sole power to vote or to direct the vote: 0

     


    (ii)
    Shared power to vote or to direct the vote: 3,292,250

     


    (iii) Sole power to dispose of or to direct the disposition of: 0

     


    (iv)
    Shared power to dispose of or to direct the disposition of: 3,292,250

     

    *
    All percentages in this Schedule 13G are based on 10,634,166 Ordinary Shares of the Issuer’s issued and outstanding as of September 30, 2022.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    Not applicable.

     



     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 2, 2023


      MEDICA III MANAGEMENT CO
       
      By: /s/ Ehud Geller
      Name: Ehud Geller
      Title: General Partner
       
      MEDICA III MANAGEMENT L.P.
       
      By: Medica III Management Co., its general partner
       
      By: /s/ Ehud Geller
      Name: Ehud Geller
      Title: General Partner
       
      MEDICA III MANAGEMENT CO.
      MEDICA III INVESTMENTS (INTERNATIONAL) L.P.
      MEDICA III INVESTMENTS (ISRAEL) L.P.
      MEDICA III INVESTMENTS (S.F.) L.P.
      MEDICA III INVESTMENTS (P.F.) L.P.
      MEDICA III INVESTMENTS (ISRAEL) (B) L.P.
      POALIM MEDICA INVESTMENTS L.P.
       
      By: Medica III Management L.P., its general partner
       
      By: Medica III Management Co., its general partner
       
      By: /s/ Ehud Geller
      Name: Ehud Geller
      Title:  General Partner
       
      /s/ EHUD GELLER
      EHUD GELLER

     



     

    EXHIBITS

     

    Exhibit 1 –
    Joint Filing Agreement pursuant to Rule 13d-1(k)(1)

     


    Get the next $PRFX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRFX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

      SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

      11/14/24 4:25:42 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

      SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

      11/13/24 11:18:32 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

      SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

      8/29/24 4:00:27 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRFX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

      As a result of increased software sales by the acquirer, and in accordance with the terms of the software business sale agreement, a significant number of zero-exercise-price warrants have matured—Blade Ranger now holds approximately 1 million shares and warrants exercisable at no additional cost TEL AVIV, Israel, May 27, 2025 /PRNewswire/ -- Blade Ranger Ltd. (TASE: BLRN), a company listed on the Tel Aviv Stock Exchange, announced the achievement of a first milestone in the transaction involving the sale of its DeepSolar operations to PainReform (NASDAQ:PRFX). According to the agreement, which was completed in March 2025, Blade Ranger received a package of securities that included, among o

      5/27/25 12:12:00 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

      TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), today announced the launch of a strategic pilot program with Econergy Renewable Energy Ltd., a leading European independent power producer (IPP). The project will utilize PainReform's proprietary DeepSolar™ platform, an AI-powered optimization solution designed to enhance operational efficiency and energy yield at utility-scale solar facilities. The pilot will be conducted at Econergy's 92-megawatt (MW) photovoltaic plant in Parau, Romania—one of the country's largest operational solar projects. This initiative marks the first phase of a broader collaboration between PainReform and Econergy, designed to demo

      5/7/25 4:30:00 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

      TEL AVIV, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), a clinical-stage specialty pharmaceutical company and developer of AI-powered energy optimization technologies, today announced its official expansion into the rapidly growing Smart Energy Management (SEM) sector. This move follows the successful acquisition of DeepSolar, a cutting-edge provider of AI-driven software solutions designed to optimize solar energy usage in residential and utility-scale solar power plants. This strategic expansion marks an important milestone in PainReform's long-term diversification strategy, aimed at tapping into high-growth, tech-enabled markets. With global solar capacity a

      4/10/25 8:30:00 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRFX
    Leadership Updates

    Live Leadership Updates

    See more
    • PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

      HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

      3/18/21 9:15:00 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

      HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

      1/6/21 8:30:00 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRFX
    SEC Filings

    See more
    • SEC Form EFFECT filed by PainReform Ltd.

      EFFECT - PAINREFORM LTD. (0001801834) (Filer)

      5/12/25 12:15:17 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by PainReform Ltd.

      424B3 - PAINREFORM LTD. (0001801834) (Filer)

      5/9/25 4:39:05 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PainReform Ltd.

      6-K - PAINREFORM LTD. (0001801834) (Filer)

      5/7/25 4:41:40 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care